NASDAQALMS

ismagilov Clinical-stage biopharmaceutical company Alumis (NASDAQ:ALMS) is having a rough day on its first day of trading with shares trading well below its IPO price of $16/share. As of 130p ET, shares were trading at $12.50, an almost 22% decline from its IPO price. Although the IPO was priced atContinue Reading